BBC3
BBC3 (BCL2 binding component 3, also known as PUMA and JFY1) is a member of the BCL-2 family of proteins and belongs to the BH3-only pro-apoptotic subclass. It promotes apoptosis by acting on mitochondria and engaging anti-apoptotic BCL-2 family members. Browse Assay Genie's current range of BBC3 research reagents below, or read on for the biology behind the target.
BBC3 is a pro-apoptotic member of the BCL-2 family and sits in the BH3-only subclass. According to the NCBI Gene summary, the protein cooperates with direct activator proteins to induce mitochondrial outer membrane permeabilisation, a decisive step in apoptosis. It can also bind anti-apoptotic BCL-2 family members, which leads to mitochondrial dysfunction and caspase activation. The UniProt function annotation for the protein notes only that it does not affect cell growth.
The human BBC3 gene is classified by HGNC in the BCL2 homology region 3 (BH3) only gene group. It is also listed among the microRNA protein coding host genes. Alternative splicing produces multiple transcript variants, and the UniProt entry name for the protein is Bcl-2-binding component 3, isoforms 3/4. Mouse and rat each have a Bbc3 ortholog, so the BBC3 protein can be studied in common rodent models.
The gene is known by the aliases PUMA and JFY1 as well as by its approved name, BCL2 binding component 3. Because of its pro-apoptotic role, BBC3 is regarded as a potential drug target for cancer therapy and for tissue injury. Researchers therefore study the BBC3 gene and protein to understand how cell death is triggered through the mitochondrial pathway and how that process might be modulated.
BBC3 is a BH3-only pro-apoptotic protein that cooperates with direct activators to induce mitochondrial outer membrane permeabilisation and apoptosis.
BBC3 binds anti-apoptotic BCL-2 family members, making it a useful subject for studying how family proteins regulate mitochondrial integrity.
Because of its pro-apoptotic role, the BBC3 gene is considered a potential drug target for cancer therapy.
BBC3 is also regarded as a potential drug target for tissue injury, linking its cell death function to damage responses.
BBC3 is a BH3-only pro-apoptotic member of the BCL-2 family. It cooperates with direct activator proteins to induce mitochondrial outer membrane permeabilisation and apoptosis, and it can bind anti-apoptotic BCL-2 family members to cause mitochondrial dysfunction and caspase activation.
BBC3 is also called PUMA and JFY1, and its full name is BCL2 binding component 3. Alternative splicing gives multiple transcript variants, and the UniProt protein name refers to isoforms 3/4. Check the datasheet of any product for its validated reactivity.
Because BBC3 promotes apoptosis, the NCBI Gene summary describes the gene as a potential drug target for cancer therapy and for tissue injury. Mouse and rat both carry a Bbc3 ortholog, which allows work in rodent models.
Other BCL-2 family members, BH3-only proteins and apoptosis pathway targets with products at Assay Genie.
Gene and protein annotations from HGNC, NCBI Gene and UniProt Q96PG8; product specifications from Assay Genie datasheets.